LSR 2000
Alternative Names: LSR-2000Latest Information Update: 16 Nov 2022
At a glance
- Originator Lusaris Therapeutics
- Class Antimigraines; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cluster headache; Migraine
Most Recent Events
- 11 Nov 2022 Preclinical trials in Cluster headache in USA (PO)(Lusaris therapeutics pipeline, November 2022)
- 11 Nov 2022 Preclinical trials in Migraine in USA (PO)(Lusaris therapeutics pipeline, November 2022)